{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:36:52Z","timestamp":1778269012258,"version":"3.51.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11938-018-0175-1","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T05:11:00Z","timestamp":1517893860000},"page":"129-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"16","author":[{"given":"Marjolijn","family":"Duijvestein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Battat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert R.","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"issue":"21","key":"175_CR1","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066\u201378.","journal-title":"N Engl J Med"},{"issue":"1","key":"175_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ibd.21417","volume":"17","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn\u2019s disease in population-based cohorts. Inflamm Bowel Dis. 2011;17(1):471\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"175_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/gut.40.4.443","volume":"40","author":"SJ Deventer Van","year":"1997","unstructured":"Van Deventer SJ. Tumour necrosis factor and Crohn\u2019s disease. Gut. 1997;40(4):443\u20138.","journal-title":"Gut"},{"issue":"9","key":"175_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"\u2022\u2022 Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324\u201338. This article provides evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD.","journal-title":"Am J Gastroenterol"},{"key":"175_CR5","first-page":"CD000543","volume":"4","author":"Y Wang","year":"2016","unstructured":"Wang Y, Parker CE, Bhanji T, Feagan BG, JK MD. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.","journal-title":"Cochrane Database Syst Rev."},{"key":"175_CR6","doi-asserted-by":"crossref","unstructured":"Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;(5):Cd000544.","DOI":"10.1002\/14651858.CD000544.pub4"},{"key":"175_CR7","first-page":"CD008870","volume":"7","author":"WC Lim","year":"2016","unstructured":"Lim WC, Wang Y, JK MD, Hanauer S. Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst Rev. 2016;7:CD008870.","journal-title":"Cochrane Database Syst Rev"},{"key":"175_CR8","first-page":"CD007698","volume":"10","author":"ME Sherlock","year":"2010","unstructured":"Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;10:CD007698.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"175_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","volume":"143","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143(5):1218\u201326 e1\u20132.","journal-title":"Gastroenterology"},{"issue":"3","key":"175_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","volume":"63","author":"SP Travis","year":"2014","unstructured":"Travis SP, Danese S, Kupcinskas L, Alexeeva O, D\u2019haens G, Gibson PR, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63(3):433\u201341.","journal-title":"Gut"},{"issue":"6","key":"175_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","volume":"29","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn\u2019s disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29(6):643\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"175_CR12","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","volume":"357","author":"AK Waljee","year":"2017","unstructured":"Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.","journal-title":"BMJ"},{"key":"175_CR13","first-page":"CD006792","volume":"2","author":"EI Benchimol","year":"2008","unstructured":"Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2008;2:CD006792.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9613","key":"175_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. Lancet. 2008;371(9613):660\u20137.","journal-title":"Lancet"},{"key":"175_CR15","first-page":"CD003459","volume":"12","author":"MD JW","year":"2012","unstructured":"JW MD, Tsoulis DJ, Macdonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn\u2019s disease. Cochrane Database Syst Rev. 2012;12:CD003459.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"175_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199502023320503","volume":"332","author":"BG Feagan","year":"1995","unstructured":"Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators. N Engl J Med. 1995;332(5):292\u20137.","journal-title":"N Engl J Med"},{"issue":"9","key":"175_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/00042737-200409000-00018","volume":"16","author":"SY Soon","year":"2004","unstructured":"Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16(9):921\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"175_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","volume":"145","author":"J Pan\u00e9s","year":"2013","unstructured":"Pan\u00e9s J, L\u00f3pez-SanRom\u00e1n A, Bermejo F, Garc\u00eda-S\u00e1nchez V, Esteve M, Torres Y, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn\u2019s disease. Gastroenterology. 2013;145(4):766\u201374.e1.","journal-title":"Gastroenterology"},{"key":"175_CR19","doi-asserted-by":"crossref","unstructured":"Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, et al. Early administration of azathioprine vs conventional management of Crohn\u2019s Disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758\u201365.e2. quiz e14\u20135","DOI":"10.1053\/j.gastro.2013.04.048"},{"key":"175_CR20","doi-asserted-by":"crossref","unstructured":"Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153(3):835\u201357. e6","DOI":"10.1053\/j.gastro.2017.07.031"},{"issue":"2","key":"175_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2013.441","volume":"109","author":"GR Lichtenstein","year":"2014","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, et al. Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT Registry. Am J Gastroenterol. 2014;109(2):212\u201323.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"175_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","volume":"13","author":"DS Kotlyar","year":"2015","unstructured":"Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847\u201358 e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"175_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2036.2010.04330.x","volume":"32","author":"MA Smith","year":"2010","unstructured":"Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32(2):119\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9317","key":"175_CR24","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"issue":"3","key":"175_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn\u2019s disease. N Engl J Med. 2007;357(3):239\u201350.","journal-title":"N Engl J Med"},{"issue":"1","key":"175_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365.","journal-title":"Gastroenterology"},{"key":"175_CR27","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85\u201395. quiz e14\u20135","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"175_CR28","doi-asserted-by":"crossref","unstructured":"Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease. Gastroenterology. 2010;138(2):463\u20138. quiz e10\u20131","DOI":"10.1053\/j.gastro.2009.09.056"},{"key":"175_CR29","first-page":"CD006893","volume":"1","author":"BW Behm","year":"2008","unstructured":"Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2008;1:CD006893.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"175_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","volume":"34","author":"S Danese","year":"2011","unstructured":"Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn\u2019s disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther. 2011;34(1):1\u201310.","journal-title":"Aliment Pharmacol Ther"},{"key":"175_CR31","first-page":"CD008794","volume":"2","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"175_CR32","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"175_CR33","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"175_CR34","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"\u2022\u2022 Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316. First prospective randomized trial on switching from originator infliximab to biosimilar.","journal-title":"Lancet"},{"issue":"4","key":"175_CR35","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2017.08.049","volume":"153","author":"R Khanna","year":"2017","unstructured":"Khanna R, Zou G. Is a biosimilar interchangeable with an originator? Gastroenterology. 2017;153(4):1160\u20132.","journal-title":"Gastroenterology"},{"key":"175_CR36","unstructured":"FDA. Considerations in demonstrating interchangeability with a reference product. 2017."},{"issue":"20","key":"175_CR37","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med"},{"issue":"1","key":"175_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","volume":"74","author":"C Berlin","year":"1993","unstructured":"Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74(1):185\u201395.","journal-title":"Cell"},{"issue":"8","key":"175_CR39","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"8","key":"175_CR40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"175_CR41","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment had failed. Gastroenterology. 2014;147(3):618\u201327 e3.","journal-title":"Gastroenterology"},{"key":"175_CR42","doi-asserted-by":"crossref","unstructured":"Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, et al. Responsiveness of endoscopic indices of disease activity for Crohn\u2019s disease. Am J Gastroenterol. 2017;","DOI":"10.1038\/ajg.2017.120"},{"issue":"5804","key":"175_CR43","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461\u20133.","journal-title":"Science"},{"issue":"10","key":"175_CR44","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1097\/MD.0000000000000613","volume":"94","author":"X Wang","year":"2015","unstructured":"Wang X, Wu T, Zhou F, Liu S, Zhou R, Zhu S, et al. IL12p40 regulates functional development of human CD4+ T cells: enlightenment by the elevated expressions of IL12p40 in patients with inflammatory bowel diseases. Medicine (Baltimore). 2015;94(10):e613.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"175_CR45","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","volume":"43","author":"JR Maxwell","year":"2015","unstructured":"Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity. 2015;43(4):739\u201350.","journal-title":"Immunity"},{"issue":"20","key":"175_CR46","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"\u2022\u2022 Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360. Phase III results on ustekinumab for CD.","journal-title":"N Engl J Med"},{"issue":"12","key":"175_CR47","first-page":"1441","volume":"13","author":"AB Gottlieb","year":"2014","unstructured":"\u2022 Gottlieb AB, Kalb RE, Langley RG, Krueger GG, de Jong EM, Guenther L, et al. Safety observations in 12,095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13(12):1441\u20138. Safety observations obtained in an international registry (PSOLAR) concerning biologic therapy.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"175_CR48","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5\u00a0years of follow-up. Br J Dermatol. 2013;168(4):844\u201354.","journal-title":"Br J Dermatol"},{"issue":"4","key":"175_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","volume":"63","author":"C Tillack","year":"2014","unstructured":"Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut. 2014;63(4):567\u201377.","journal-title":"Gut"},{"issue":"3","key":"175_CR50","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.gtc.2017.05.013","volume":"46","author":"P Deepak","year":"2017","unstructured":"Deepak P, Sandborn WJ. Ustekinumab and anti-interleukin-23 agents in Crohn\u2019s disease. Gastroenterol Clin N Am. 2017;46(3):603\u201326.","journal-title":"Gastroenterol Clin N Am"},{"issue":"1","key":"175_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10787-011-0104-6","volume":"20","author":"S Thomas","year":"2012","unstructured":"Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn\u2019s disease and ulcerative colitis. Inflammopharmacology. 2012;20(1):1\u201318.","journal-title":"Inflammopharmacology"},{"issue":"9940","key":"175_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","volume":"384","author":"S Vermeire","year":"2014","unstructured":"\u2022\u2022 Vermeire S, O\u2019Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309\u201318. Phase II results on etroluzimab for UC.","journal-title":"Lancet"},{"issue":"6","key":"175_CR53","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.173","volume":"5","author":"F Mullershausen","year":"2009","unstructured":"Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol. 2009;5(6):428\u201334.","journal-title":"Nat Chem Biol"},{"issue":"5","key":"175_CR54","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"175_CR55","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","volume":"168","author":"J Camm","year":"2014","unstructured":"Camm J, Hla T, Bakshi R, Brinkmann V. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014;168(5):632\u201344.","journal-title":"Am Heart J."},{"issue":"18","key":"175_CR56","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"\u2022\u2022 Sandborn WJ, Feagan BG, Wolf DC, D\u2019Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754\u201362. Phase II results on ozanimod for UC.","journal-title":"N Engl J Med"},{"issue":"1","key":"175_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/01.MIB.0000194183.92671.b6","volume":"12","author":"IJ Fuss","year":"2006","unstructured":"Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn\u2019s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflammatory Bowel Diseases. 2006;12(1):9\u201315.","journal-title":"Inflammatory Bowel Diseases."},{"issue":"2","key":"175_CR58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","volume":"38","author":"M Coskun","year":"2017","unstructured":"Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127\u201342.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"175_CR59","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng MW, Bowman EP, JJ ME, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719\u201329.","journal-title":"Nat Med."},{"key":"175_CR60","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Feagan BG, Sandborn WJ, D\u2019Haens, G, Panes J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017. Phase II results on risankizumab for CD.","DOI":"10.1016\/S0140-6736(17)30570-6"},{"issue":"1","key":"175_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","volume":"153","author":"BE Sands","year":"2017","unstructured":"\u2022\u2022 Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study. Gastroenterology. 2017;153(1):77\u201386 e6. Phase II results on brazikumab for CD.","journal-title":"Gastroenterology"},{"issue":"7422","key":"175_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins L, Ripke S, Weersma RK, Duerr RH, DP MG, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119\u201324.","journal-title":"Nature"},{"issue":"1","key":"175_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273\u201387.","journal-title":"Immunol Rev"},{"issue":"3","key":"175_CR64","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.gtc.2017.05.015","volume":"46","author":"BS Boland","year":"2017","unstructured":"Boland BS, Vermeire S. Janus kinase antagonists and other novel small molecules for the treatment of Crohn\u2019s disease. Gastroenterol Clin N Am. 2017;46(3):627\u201344.","journal-title":"Gastroenterol Clin N Am"},{"issue":"18","key":"175_CR65","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"\u2022\u2022 Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336. Phase III results on tofacitinib for UC.","journal-title":"N Engl J Med"},{"issue":"10066","key":"175_CR66","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"\u2022\u2022 Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266\u201375. Phase II results on filgotinib for CD.","journal-title":"Lancet"},{"key":"175_CR67","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Panes J, D\u2019Haens GR, Colombel JF, Zhou Q, et al. Safety and efficacy of ABT-494 (upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from Celest. Gastroenterology. 152(5):S1308\u2013S9.","DOI":"10.1016\/S0016-5085(17)34357-3"},{"issue":"3","key":"175_CR68","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","volume":"14","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet L, Panes J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016;14(3):348\u201354.e17.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"175_CR69","doi-asserted-by":"crossref","unstructured":"Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, et al. Development of clinical prediction models for surgery and complications in Crohn\u2019s disease. J Crohns Colitis. 2017.","DOI":"10.1093\/ecco-jcc\/jjx130"},{"issue":"3","key":"175_CR70","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","volume":"130","author":"L Beaugerie","year":"2006","unstructured":"Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn\u2019s disease. Gastroenterology. 2006;130(3):650\u20136.","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"175_CR71","first-page":"A-17","volume":"132","author":"C Loly","year":"2007","unstructured":"Loly C, Belaiche J, Louis E. Predictors of severe Crohn\u2019s disease. Gastroenterol Clin N Am. 2007;132(Suppl 2):A-17.","journal-title":"Gastroenterol Clin N Am"},{"issue":"3","key":"175_CR72","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.gtc.2017.05.010","volume":"46","author":"R Khanna","year":"2017","unstructured":"Khanna R, Jairath V, Feagan BG. The evolution of treatment paradigms in Crohn\u2019s disease: beyond better drugs. Gastroenterol Clin N Am. 2017;46(3):661\u201377.","journal-title":"Gastroenterol Clin N Am"},{"issue":"1","key":"175_CR73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.crohns.2009.12.003","volume":"4","author":"G Assche Van","year":"2010","unstructured":"Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: definitions and diagnosis. J Crohns Colitis. 2010;4(1):7\u201327.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"175_CR74","first-page":"652","volume":"7","author":"AJ Yarur","year":"2011","unstructured":"Yarur AJ, Strobel SG, Deshpande AR, Abreu MT. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7(10):652\u20139.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"12","key":"175_CR75","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","volume":"5","author":"IC Solberg","year":"2007","unstructured":"Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn\u2019s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"175_CR76","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ibd.20036","volume":"13","author":"T Jess","year":"2007","unstructured":"Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"175_CR77","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","volume":"7","author":"S Schreiber","year":"2013","unstructured":"Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3\u00a0years for adalimumab-treated patients with early Crohn\u2019s disease. J Crohns Colitis. 2013;7(3):213\u201321.","journal-title":"J Crohns Colitis"},{"issue":"15","key":"175_CR78","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362(15):1383\u201395.","journal-title":"N Engl J Med"},{"issue":"10006","key":"175_CR79","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","volume":"386","author":"R Khanna","year":"2015","unstructured":"\u2022 Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386(10006):1825\u201334. This prospective study demonstrates that although early combinedimmunosuppression (TNF antagonist and antimetabolite) was not more effective than conventional management for controlling Crohn\u2019s disease symptoms, the risk of major adverse outcomes was lower.","journal-title":"Lancet"},{"issue":"1","key":"175_CR80","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.13001","volume":"41","author":"R Khanna","year":"2015","unstructured":"Khanna R, Zou G, DHaens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity. Aliment Pharmacol Ther. 2015;41(1):77\u201386.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"175_CR81","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/apt.13408","volume":"42","author":"V Jairath","year":"2015","unstructured":"Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42(10):1200\u201310.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"175_CR82","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","volume":"133","author":"KF Froslie","year":"2007","unstructured":"Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412\u201322.","journal-title":"Gastroenterology"},{"issue":"3","key":"175_CR83","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","volume":"12","author":"JF Colombel","year":"2014","unstructured":"Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, et al. Adalimumab induces deep remission in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12(3):414\u201322.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"175_CR84","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","volume":"14","author":"SC Shah","year":"2016","unstructured":"\u2022 Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(9):1245\u201355 e8. A meta-analysis showing that mucosal healing is with long-term clinical remission, avoidance of colectomy, and corticosteroid-free clinical remission.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"175_CR85","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","volume":"141","author":"JF Colombel","year":"2011","unstructured":"Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194\u2013201.","journal-title":"Gastroenterology"},{"issue":"3","key":"175_CR86","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","volume":"65","author":"RV Bryant","year":"2016","unstructured":"Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6\u00a0years of follow-up. Gut. 2016;65(3):408\u201314.","journal-title":"Gut"},{"key":"175_CR87","unstructured":"\u2022 Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017. Histological remission better predicts lower rates of corticosteroid use and acute severe colitis requiring hospitalization, over a median of 6\u00a0years of follow-up."},{"issue":"1","key":"175_CR88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/gutjnl-2015-310393","volume":"66","author":"MH Mosli","year":"2017","unstructured":"Mosli MH, Feagan BG, Zou G, Sandborn WJ, D\u2019Haens G, Khanna R, et al. Development and validation of a histological index for UC. Gut. 2017;66(1):50\u20138.","journal-title":"Gut"},{"issue":"2","key":"175_CR89","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0016-5085(98)70476-7","volume":"114","author":"GR D\u2019Haens","year":"1998","unstructured":"D\u2019Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn\u2019s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262\u20137.","journal-title":"Gastroenterology."},{"issue":"11","key":"175_CR90","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1097\/MIB.0000000000000155","volume":"20","author":"A Mojtahed","year":"2014","unstructured":"Mojtahed A, Khanna R, Sandborn WJ, D\u2019Haens GR, Feagan BG, Shackelton LM, et al. Assessment of histologic disease activity in Crohn\u2019s disease: a systematic review. Inflamm Bowel Dis. 2014;20(11):2092\u2013103.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"175_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MCG.0000000000000507","volume":"51","author":"GT Brennan","year":"2017","unstructured":"Brennan GT, Melton SD, Spechler SJ, Feagins LA. Clinical implications of histologic abnormalities in ileocolonic biopsies of patients with Crohn\u2019s disease in remission. J Clin Gastroenterol. 2017;51(1):43\u20138.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"175_CR92","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","volume":"11","author":"CA Solem","year":"2005","unstructured":"Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflammatory Bowel Disease. 2005;11(8):707\u201312.","journal-title":"Inflammatory Bowel Disease"},{"key":"175_CR93","doi-asserted-by":"crossref","unstructured":"Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802\u201319. quiz 20","DOI":"10.1038\/ajg.2015.120"},{"issue":"11","key":"175_CR94","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","volume":"6","author":"J Jones","year":"2008","unstructured":"Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2008;6(11):1218\u201324.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10114","key":"175_CR95","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2018","unstructured":"\u2022 Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390(10114):2779\u201389. The first study to show that timely escalation with an anti-tumor necrosis factor therapy on the basis of clinical symptoms combined with biomarkers in patients with early CD results in better clinical and endoscopic outcomes than symptom-driven decisions alone.","journal-title":"Lancet"},{"issue":"3","key":"175_CR96","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"\u2022 Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, American Gastroenterological Association Institute Clinical Guidelines C. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827\u201334. Current guideline of the American Gastroenterological Association Institute on therapeutic drug monitoring in IBD.","journal-title":"Gastroenterology"},{"issue":"3","key":"175_CR97","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40262-015-0316-9","volume":"55","author":"M Coskun","year":"2016","unstructured":"Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin Pharmacokinet. 2016;55(3):257\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"175_CR98","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","volume":"7","author":"M Bortlik","year":"2013","unstructured":"Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn\u2019s disease. J Crohn\u2019s Colitis. 2013;7(9):736\u201343.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"6","key":"175_CR99","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","volume":"147","author":"OJ Adedokun","year":"2014","unstructured":"Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296\u2013307 e5.","journal-title":"Gastroenterology"},{"issue":"3","key":"175_CR100","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.gastro.2017.07.039","volume":"153","author":"American Gastroenterological A","year":"2017","unstructured":"American Gastroenterological A. Therapeutic drug monitoring in inflammatory bowel disease: clinical decision support tool. Gastroenterology. 2017;153(3):858\u20139.","journal-title":"Gastroenterology"},{"issue":"4","key":"175_CR101","doi-asserted-by":"publisher","first-page":"e93498","DOI":"10.1371\/journal.pone.0093498","volume":"9","author":"F Beigel","year":"2014","unstructured":"Beigel F, Friedrich M, Probst C, Sotlar K, Goke B, Diegelmann J, et al. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. PloS One. 2014;9(4):e93498.","journal-title":"PloS One"},{"key":"175_CR102","doi-asserted-by":"crossref","unstructured":"\u2022 West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579\u201389. This study shows that high expression of oncostatin M is strongly associated with failure of anti-TNF therapy.","DOI":"10.1038\/nm.4307"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-018-0175-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T23:21:34Z","timestamp":1660432894000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-018-0175-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s11938-018-0175-1","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"6 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Robert Battat declares no conflict of interest.Marjolijn Duijvestein reports nonfinancial support from Dr. Falk Pharma and personal fees from Janssen, Merck & Co., Inc., Pfizer, and Tillotts Pharam.Niels Vande Casteele reports personal fees from Janssen, Pfizer, Takeda, UCB Pharma, and Boehringer Ingelheim.Geert R. D\u2019Haens reports grants from Photophill and grants and personal fees from Abbvie, Ferring, Dr. Falk Pharma, Johnson and Johnson, Millenium\/Takeda, MSD, Mundipharma, and Prometheus laboratories\/Nestle.Dr. D\u2019Haens also received personal fees from Ablynx, Amaken, Amgen, AM Pharma, Avaxia, Biogen, BMS, Celgene, Boerhinger Ingelheim, Celltrion, Cosmo, Covidien\/Medtronics, Eli Lilly, Engene, Galapagos, Genentech\/Roche, GSK, Gilead, Lycera, Medimetrics, MitsubishiPharma, Nextbiotics, Novonordisk, Norgine, Otsuka, Pfizer, Protagonist, Receptos\/Celgene, Salix, Sandoz, Setpoint, Shire, TEVA, Tigenix, Tillotts, Versant, and Vifor.William J. Sandborn reports personal fees and nonfinancial support from Robarts Clinical Trials (wholey owned by Western University, London, Ontario, Canada). Dr. Sandborn has also received grants and personal fees from Prometheus Laboratories, AbbVie, Boehringer Ingelheim, Takeda, Atlantic Pharmaceuticals, Janssen, Bristol-Myers Squibb, Genentech, and Nutrition Science Partners and personal fees from Kyowa Hakko Kirin, Millennium Pharmaceuticals, Celgene Cellular Therapeutics, Santarus, Salix Pharmaceuticals, Catabasis Pharmaceuticals, Vertex Pharmaceuticals, Warner Chilcott, Gilead Sciences, Cosmo Pharmaceuticals, Ferring Pharmaceuticals, Sigmoid Biotechnologies, Tillotts Pharma, Am Pharma BV, Dr. August Wolff, Avaxia Biologics, Zyngenia, Ironwood Pharmaceuticals, Index Pharmaceuticals, Nestle, Lexicon Pharmaceuticals, UCB Pharma, Orexigen, Luitpold Pharmaceuticals, Baxter Healthcare, Ferring Research Institute, Amgen, Novo Nordisk, Mesoblast Inc., Shire, Ardelyx Inc., Actavis, Seattle Genetics, MedImmune (AstraZeneca), Actogenix NV, Lipid Therapeutics Gmbh, Eisai, Qu Biologics, Toray Industries Inc., Teva Pharmaceuticals, Eli Lilly, Chiasma, TiGenix, Adherion Therapeutics, Immune Pharmaceuticals, Celgene, Arena Pharmaceuticals, Ambrx Inc., Akros Pharma, Vascular Biogenics, Theradiag, Forward Pharma, Regeneron, Galapagos, Seres Health, Ritter Pharmaceuticals, Theravance, Palatin, and Biogen. In addition, Dr. Sandborn has a patent Topical azathioprine to treat inflammatory bowel disorders (US 5,691,343) issued, a patent Topical formulations of azathioprine to treat inflammatory bowel disorders (US 5,905,081) issued, a patent Colonic delivery of nicotine to treat inflammatory bowel disease (South African patent 97\/1020; US 5,846,983, 5,889,028, and 6,166,044; Mexico patent 209,636; Europe patents 0954337 and 893,998; Hong Kong patent HK1019043; China patent ZL97192177; Czech patent 293,616; Canada patent 2,246,235) issued, a patent The use of azathioprine to treat Crohn\u2019s disease (US 5,733,915) issued, a patent Azathioprine compositions for colonic administration (New Zealand patent 306062; Singapore patent 45647; Australia patent 707168; Czech patent 290428) issued, a patent Intestinal absorption of nicotine to treat nicotine responsive conditions (Australia patent 718052; US 6,238,689) issued, a patent The use of topical azathioprine and thioguanine to treat colorectal adenomas (US 6,166,024) issued, a patent Enema and enterically coated oral dosage forms of azathioprine (US 6,432,967) issued, a patent A pharmaceutical composition for the treatment of inflammatory bowel disease (US 7,341,741) issued, a patent Intestinal absorption of nicotine to treat nicotine responsive conditions (Canada patent 2,260,909) issued, and a patent Obesity treatment and device (US 7,803,195 B2) licensed to Enteromedics.Reena Khanna reports personal fees from AbbVie, Janssen, Pfizer, Shire, and Takeda.Vipul Jairath reports personal fees from Janssen, Takeda, Abbvie, Ferring, and Pfizer.Brian G. Feagan reports grants and personal fees from AbbVie, Amgen, Astra Zeneca, Bristol-Meyers Squibb (BMS), Janssen Biotech\/Centocor, JnJ\/Janssen, Pfizer, Receptos, and Takeda. Dr. Feagan also reports personal fees from Actogenix, Akros, Albireo Pharma, Allergan, Avaxia Biologics Inc., Avir Pharma, Atlantic Pharma, Baxter Healthcare Corporation, Biogen Idec, Boehringer-Ingelheim, Calypso Biotech, Celgene, Elan\/Biogen, EnGene, Ferring, Genentech\/Roche, GiCare Pharma, Gilead, Given Imaging, GSK, Ironwood, Kyowa Kakko Kirin Co Ltd., Lilly, Lycera Biotech, Merck, Mesoblast Pharma, Millennium, Nestles, Novo Nordisk, Novartis, Prometheus Therapeutics & Diagnostics, Protagonist, Salix, Shire, Sigmoid Pharma, Synergy Pharma, Teva Pharma, TiGenix, Tillotts, UCB, Vertex, VHsquared, Wyeth, Zealand, Zyngenia, Galapagos, Inception IBD Inc., Lexicon, Vivelix Pharma, Japan Tobacco Company, Ablynx, Progenity, and NextBiotix. Dr. Feagan has also received a grant from Sanofi and is Senior Scientific Officer, Robarts Clinical Trials Inc., Western University, London, Ontario, Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}